JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trulson, M. E.
Right arrow Articles by Jacobs, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trulson, M. E.
Right arrow Articles by Jacobs, B. L.

Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5,7-dihydroxytryptamine

ME Trulson, EE Eubanks and BL Jacobs

Previous studies have established that a complex behavioral syndrome-- consisting of tremor, rigidity, hindlimb abduction. Straub tail, lateral head weaving and reciprocal forepaw treading--is a specific reflection of the activity of central serotonin receptors. This syndrome was utilized in the present study to test for supersensitivity in the central serotonergic system. Specific destruction of central serotonin nerve terminals by intraventricular injection of 5,7- dihydroxytryptamine (5,7-DHT, 50 mug) in adult male rats pretreated with a catecholamine uptake blocking agent resulted in marked supersensitivity to serotonin precursors and agonists. The greatest degree of supersensitivity was observed in response to L-5- hydroxytryptophan, for which the ED50 for elicitation of the syndrome was 20% of the value for control rats. A lesser degree of supersensitivity was seen in response to L-tryptophan (following monoamine oxidase inhibition) and the direct-acting serotonin agonist, 5-methoxy-N,N-dimethyltryptamine, for which the ED50 was approximately 50% of the control value in both cases. Supersensitivity begins to develop within 24 hours and is relatively complete by 96 hours after 5,7-DHT. A marked subsensitivity to the serotonin releasing agent, fenfluramine, was found in 5,7-DHT-treated rats. In contrast to the marked supersensitivity to serotonin precursors and agonists which occurs following 5,7-DHT, chronic administration of a serotonin synthesis inhibitor, p-chlorophenylalanine (400 mg/kg every 3 days for a total of 24 days), did not produce supersensitivity to L-5- hydroxytryptophan or 5-methoxy-N,N-dimethyltryptamine. Possible pre- and postsynaptic mechanisms for the development of supersensitivity are discussed.

Volume 198, Issue 1, pp. 23-32, 07/01/1976
Copyright © 1976 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Neurosci.Home page
M. H. Baumann, M. A. Ayestas, and R. B. Rothman
Functional Consequences of Central Serotonin Depletion Produced by Repeated Fenfluramine Administration in Rats
J. Neurosci., November 1, 1998; 18(21): 9069 - 9077.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
M. H. BAUMANN, M. A. AYESTAS, and R. B. ROTHMAN
In Vivo Correlates of Central Serotonin Function after High-Dose Fenfluramine Administration
Ann. N.Y. Acad. Sci., May 30, 1998; 844(1): 138 - 152.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
H.G. Series, M. le Masurier, S.E. Gartside, M. Franklin, and T. Sharp
Behavioural and neuroendocrine responses to D-fenfluramine in rats treated with neurotoxic amphetamines
J Psychopharmacol, January 1, 1995; 9(3): 214 - 222.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics.